REN-1654

N/A

Report date: 2022/07/19 16:22:54
NME

Base Information

Drug NameREN-1654
Drug Alias NameREN-1654CPI-1189REN-1189
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionP38 mitogen-activated protein kinase inhibitorsTumor necrosis factor α inhibitors
TargetsP38 mitogen-activated protein kinaseTumor necrosis factor α
Therapy Area/IndicationsRadiculopathyNeuralgiaSciatica +[8] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusDiscontinued (Phase 2 Clinical)
Highest Status in ChinaN/A
Originator CompaniesEvotec
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesCentaur PharmaceuticalsRenovis
Active IndicationsN/A
Inactive IndicationsRadiculopathyNeuralgiaSciatica +[8] 

Other Information

ATC CodeN/A
Related LinksN/A